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Effects of Exercise Intensity and Altered  
Substrate Availability on Cardiovascular  
and Metabolic Responses to Exercise  
After Oral Carnitine Supplementation in Athletes
Elizabeth M. Broad, Ronald J. Maughan, and Stuart D.R. Galloway
The effects of 15 d of supplementation with L-carnitine L-tartrate (LC) on metabolic responses to graded-
intensity exercise under conditions of altered substrate availability were examined. Fifteen endurance-trained 
male athletes undertook exercise trials after a 2-d high-carbohydrate diet (60% CHO, 25% fat) at baseline 
(D0), on Day 14 (D14), and after a single day of high fat intake (15% CHO, 70% fat) on Day 15 (D15) in a 
double-blind, placebo-controlled, pair-matched design. Treatment consisted of 3 g LC (2 g L-carnitine/d; n = 
8) or placebo (P, n = 7) for 15 d. Exercise trials consisted of 80 min of continuous cycling comprising 20-min 
periods at each of 20%, 40%, 60%, and 80% VO2peak. There was no significant difference between whole-body 
rates of CHO and fat oxidation at any workload between D0 and D14 trials for either the P or LC group. Both 
groups displayed increased fat and reduced carbohydrate oxidation between the D14 and D15 trials (p < .05). 
During the D15 trial, heart rate (p < .05 for 20%, 40%, and 60% workloads) and blood glucose concentration 
(p < .05 for 40% and 60% workloads) were lower during exercise in the LC group than in P. These responses 
suggest that LC may induce subtle changes in substrate handling in metabolically active tissues when fatty-
acid availability is increased, but it does not affect whole-body substrate utilization during short-duration 
exercise at the intensities studied.
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L-carnitine (LC) plays a role in fat metabolism 
through its function as a transporter of long-chain fatty 
acids into mitochondria for β-oxidation (Fritz, 1963), and 
it also acts to buffer excess mitochondrial acetyl-CoA 
by forming acetylcarnitine. Thus, carnitine is involved 
in the integration of carbohydrate (CHO), amino acid, 
and fat metabolism, making it a key metabolic regula-
tor both in skeletal muscle (Roepstorff et al., 2005; 
van Loon, Greenhaff, Constantin-Teodosiu, Saris, & 
Wagenmakers, 2001) and in other important metaboli-
cally active tissues such as heart, brain, pancreas, and liver 
(Broderick et al., 1995; Harper, Wadstrom, Backman, & 
Cederblad, 1995; Hino, Nishikawa, Sato, & Inoue, 2005; 
Kai et al., 2005).
We have previously observed metabolic changes 
during cycling exercise at 60% of VO2peak in endurance-
trained males after 2 weeks of LC supplementation, 
including an increase in whole-body CHO oxidation 
and a tendency toward blunted ammonia accumulation 
during exercise (Abramowicz & Galloway, 2005; Broad, 
Maughan, & Galloway, 2008). Furthermore, substrate 
selection in cardiac muscle has been observed to shift 
toward CHO metabolism when large increases in car-
nitine availability are induced (Lopaschuk, 2000) but 
also with increases in carnitine within the physiological 
range (Rodgers, Christe, Tremblay, Babson, & Daniels, 
2001). Hyperinsulinemic-euglycemic-clamp studies 
show increased glucose disposal after carnitine supple-
mentation in controls and patients with Type 2 diabetes 
(Ferrannini et al., 1988; Giancaterini et al., 2000; Min-
grone et al., 1999), and carnitine infusion during a clamp 
results in increased muscle glycogen storage (Stephens, 
Constantin-Teodosiu, Laithwaite, Simpson, & Greenhaff, 
2006). These data suggest that carnitine can increase 
glucose disposal at rest and stimulate glucose oxidation 
during contractile activity without necessarily altering 
skeletal-muscle total carnitine content. However, it is 
also known that an elevation in skeletal-muscle carnitine 
after oral LC supplementation is achievable in humans, 
especially if the LC is consumed in combination with 
adequate CHO (Stephens, Evans, Constantin-Teodosiu, 
& Greenhaff, 2007; Wall et al., 2010).
The numerous attempts that have been made to 
determine whether LC supplementation can influence 
whole-body substrate selection at rest and during 
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exercise have produced varying results (for reviews see 
Brass & Hiatt, 1998; Galloway & Broad, 2005; Karlic 
& Lohninger, 2004; Stephens, Constantin-Teodosiu, & 
Greenhaff, 2007). The reasons for the variability in results 
are not fully understood but may relate to differences in 
exercise intensity, prior dietary intake, or training status 
of the subjects.
Exercise intensity determines the proportion of dif-
ferent fuels used for energy supply, with exercise at low 
intensity relying predominantly on plasma free fatty acids 
(FFA) as a source of fuel (Romijn et al., 1993). Recently 
it has been shown that the effect of oral carnitine supple-
mentation on substrate metabolism varies with exercise 
intensity (Wall et al., 2010). Therefore, previous studies, 
including our own, that have investigated the effects of 
LC supplementation at relatively high fixed exercise 
intensities (>60% VO2max) with high CHO availability 
(CHO replete during supplementation period, CHO-
based pretrial meal) may have restricted the ability to 
detect an impact of LC supplementation on metabolism 
during exercise.
Preexercise substrate availability is also known to 
influence substrate utilization during exercise. However, 
only one study (Decombaz, Deriaz, Acheson, Gmuender, 
& Jequier, 1993) previously examined manipulations in 
substrate availability before exercise with and without 
supplemental carnitine. Decombaz et al. examined the 
effects of an overnight fast and the effect of glycogen-
depleting exercise on substrate metabolism in healthy 
active males with and without 7 days of LC supplementa-
tion. They observed no changes in substrate use or heart-
rate response to exercise in either the overnight-fasted 
state or the glycogen-depleted state. Studies conducted at 
rest with intralipid and heparin infusion to acutely elevate 
plasma FFA also indicate no impact of LC infusion on 
basal substrate metabolism (Natali et al., 1993), but to 
date no study has examined the impact of manipulating 
exercise intensity and acutely increasing the availability 
of circulating FFA through the ingestion of high-fat 
meals on the metabolic response to exercise after LC 
supplementation.
Therefore, this study aims to further examine the 
effects of LC supplementation on substrate metabolism 
during exercise by examining the metabolic response at 
different intensities under conditions of altered substrate 
availability in well-trained subjects. We hypothesized 
that this approach could provide some insight into the 
potential effects of LC supplementation on whole-body 
substrate selection during exercise in athletes and lead 
to a better understanding of this supplement’s practical 
applications.
Methods
Sixteen nonvegetarian male athletes actively involved 
in endurance training, all with a VO2peak greater than 
50 ml · kg–1 · min–1, were recruited. One subject was 
unable to complete the study because of illness, so 
characteristics shown in Table 1 are for 15 subjects. All 
subjects were fully informed about the study, provided 
written informed consent, and underwent preparticipa-
tion screening (medical history and physical activity 
questionnaires). The study was undertaken during the 
preparation phase of the cycling and triathlon competi-
tive season to ensure that consistent endurance-based 
training was being undertaken and to avoid a training 
effect. All experimental procedures were approved by 
the university Ethics of Research Committee, and all 
subjects were free to withdraw from the study at any time 
without obligation.
The study used a double-blind, placebo-controlled, 
pair-matched parallel design based on our previous work 
indicating that plasma total carnitine concentration did 
not return to baseline for up to 4 weeks after cessation 
of oral supplementation (Broad et al., unpublished 
observations). Pair matching was undertaken primar-
ily on the basis of training history, exercise workload 
at VO2peak, and age. Subjects came to the laboratory on 
five occasions over 4–5 weeks. The first visit was used 
to determine VO2peak using an incremental cycle protocol 
after a 3-min warm-up, which commenced at 150 W and 
increased 30 W every 3 min until the subject could no 
longer maintain a cadence over 70 rpm. When a full 3 
min was not completed at the final workload, 10 W was 
added to the previously completed workload for each 
full minute accomplished to calculate the power output 
at VO2peak. Body composition was assessed using the sum 
of seven skinfold measures (biceps, triceps, subscapular, 
supraspinale, abdomen, midthigh, and calf; mean of 
duplicate measures; Norton & Olds, 2000). All exercise 
trials were undertaken on a Lode Excalibur Sport V2.1 
ergometer (Lode BV, The Netherlands) set up to the 
athletes’ training-bike measurements, with the athletes 
using their own pedals and shoes, in a laboratory where 
the temperature was maintained at 20–21 °C. All subjects 
then undertook one familiarization trial to ensure that 
loads of 20%, 40%, 60%, and 80% of VO2peak had been 
selected appropriately and to familiarize subjects with 
Table 1 Subject Characteristics, M ± SD
Variable
Placebo  
(n = 7)
LC  
(n = 8)
Age (years) 31 ± 8 34 ± 10
Height (cm) 177 ± 5 181 ± 4
Body mass (kg) 73.5 ± 10.3 77.3 ± 7.7
Skinfolds (sum of 7, mm) 61.5 ± 17.4 67.7 ± 31.6
VO2max (L/min) 5.09 ± 0.43 4.93 ± 0.56
Current cycle training (hr/
week) 7.4 ± 2.7 6.1 ± 2.3
20% workload (W) 71 ± 7 68 ± 9
40% workload (W) 141 ± 12 137 ± 18
60% workload (W) 211 ± 18 205 ± 28
80% workload (W) 282 ± 24 273 ± 37
Note. LC = L-carnitine.
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testing procedures. If subjects were found to be working 
at an inappropriate load, this was adjusted before com-
pleting the subsequent trials. All subsequent trials were 
undertaken at the same time of day.
Treatment
After the familiarization trial, subjects were pair-matched 
for allocation to active treatment with L-carnitine 
L-tartrate (LC) or placebo (P). Subjects then attended the 
laboratory at the following times: baseline measurements 
before treatment commenced (D0), after 14 days supple-
mentation (D14), and 24 hr later after high fat intake 
(D15). Treatments consisted of two capsules taken twice 
daily with meals (i.e., four capsules per day total) for 15 
days. The supplement capsule consisted of 746 mg of LC 
(L-carnipure, Lonza Ltd., Basel, Switzerland), thereby 
providing 3 g LC per day, equivalent to 2 g L-carnitine per 
day (3 g L-carnitine L-tartrate provides 2 g L-carnitine). 
The placebo capsule consisted of a methyl cellulose filler 
of the same weight as the carnitine. Subjects’ compliance 
to the treatment was assessed by checking whether any 
capsules remained at the end of 15 days, with no evidence 
of noncompliance found.
Dietary and Exercise Controls
Each subject was prescribed a dietary intake for 48 
hr before the D0 and D14 trials based on attaining an 
energy ratio of 60% CHO, 15% protein, and 25% fat 
and achieving estimated energy requirements (Burke, 
1996). These 2-day diets were designed around subjects’ 
typical dietary intake taken from a 7-day food diary. In 
the 24 hr between the D14 and D15 trials, subjects were 
provided with all the food they were to consume. This 
high-fat, low-CHO intake was individualized from two 
standard menus (Table 2) and designed to provide the 
same total energy as the previously prescribed diets in 
an energy ratio of 15% CHO, 15% protein, and 70% fat. 
Compliance was assessed on trial days by using a check-
list of the foods prescribed in the 48 hr before D0 and 
D14 trials and of the foods provided in the 24 hr before 
the D15 trial. Subjects were also asked to undertake the 
same exercise in the 48 hr before the D0 and D14 trials. 
Water was allowed ad libitum throughout each dietary 
period. Between the initial trials on D0 and the start of 
the dietary control for the D14 trial, subjects resumed 
their habitual dietary intake.
The Trials
A 24-hr urine collection was undertaken before trial com-
mencement on D0 and D14. All trials were undertaken 3 
hr after ingestion of the last supplement, which was taken 
with a standardized meal. For the trials on D0 and D14, 
this consisted of 1g/kg body mass (BM) CHO (bread and 
jam) and, for the high-fat trial, whole milk with added 
cream to match the energy and protein content of D0 and 
D14 while preserving the ratios of 70% fat, 15% CHO. On 
arrival at the laboratory, nude BM (NBM) was assessed, 
a heart-rate monitor positioned, and a cannula (20-gauge, 
SSS Healthcare) inserted into an antecubital vein. After 
5 min of seated rest a blood sample was drawn without 
stasis, along with a free-flowing capillary sample from a 
preheated hand for analysis of pH, pCO2, and bicarbon-
ate (Radiometer ABL 700, Copenhagen, Denmark). The 
cannula was kept patent at all times using a 1-ml saline 
flush after sample collections. Subjects then mounted 
the cycle ergometer, where they were equipped with a 
mouthpiece and nose clip for measurement of expired 
gas (4 min at rest).
Subjects began cycling for 20 min at 20% of power 
output at VO2peak, followed in a continuous fashion by 
20 min each at 40%, 60%, and 80% of power output at 
VO2peak (80 min total), at a self-selected pedal cadence 
(mean for P group 95 rpm, and for LC group, 89 rpm). 
Expired-gas analysis was undertaken during the last 4 
min of each 20-min workload plus midway through the 
final workload to estimate rates of CHO and fat oxida-
tion (Peronnet & Massicotte, 1991). Heart rate (HR) was 
recorded at 60-s intervals throughout the trial (PolarVan-
tage, NV, Finland) and a rating of perceived exertion 
(15-point Borg scale; Borg, 1982) recorded every 10 min 
throughout exercise. Capillary and venous blood samples 
were drawn at rest and at the end of each workload. Water 
was provided throughout the trial, with encouragement 
to achieve sufficient fluid intake to prevent dehydration, 
based on volume consumed and the change in body mass 
observed in the familiarization trial. Subjects were cooled 
with a fan throughout all trials to limit thermal stress. 
Table 2 The Two Standard Menus Used to Create the 24-hr High Fat Intake for Each Individual
Time of day Menu 1 Menu 2
Posttrial snack Peanuts (50 g) and crisps (25 g) Peanuts (50 g) and crisps (25 g)
Lunch Garden salad with 100 g avocado, 100 g coleslaw,  
30 g salad dressing, and 150 g roast chicken with skin
Garden salad with 100 g avocado, 100 g coleslaw, 30 g 
salad dressing, 100 g ham, 100 g cheese
Midafternoon 60-g Mars bar, celery with 60 g sour-cream-based dip 60-g Mars bar, celery with 60 g sour-cream-based dip
Dinner 200 ml cream-of-chicken soup; 170-g beef steak and 
onion fried in 30 ml olive oil with broccoli, carrot, 
cauliflower; chocolate mousse with 50 ml cream
200 ml cream-of-chicken soup; 170 g chicken Kiev 
with broccoli, carrot, cauliflower; chocolate mousse 
with 50 ml cream
Pretrial snack 300 ml whole milk with 50 ml cream 300 ml whole milk with 50 ml cream
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After completing the 80 min, subjects rested during the 
removal of the cannula, towel-dried, and then recorded 
their final NBM.
Blood and Urine Analysis
Venous blood (2.5 ml) was drawn at rest and every 20 min 
during exercise. Duplicate 100-μl aliquots of whole blood 
were immediately deproteinized in 1 ml chilled 0.4-M 
perchloric acid, shaken vigorously, and kept on ice until 
centrifugation at 10,000 rpm for 3 min. Samples were 
subsequently frozen at –20 °C until analysis. Blood lac-
tate (Maughan, 1982) and glycerol (Boobis & Maughan, 
1983) concentrations were measured by fluorometric 
enzymatic assays (Jenway 6200 fluorimeter, Jenway Ltd., 
Essex). The remaining blood was mixed well in EDTA 
tubes, and duplicate samples were drawn into capillary 
tubes that were sealed and centrifuged at 10,000 rpm 
before hematocrit measurement (Hawksley Microhema-
tocrit reader, Hawksley & Sons, Sussex). A 1.5-ml portion 
of the blood sample was then centrifuged before duplicate 
aliquots of plasma were drawn off for glucose and FFA 
analysis. The remaining whole blood was mixed well 
before analysis for hemoglobin. Plasma glucose (Sigma 
Diagnostic), FFA (Wako Chemicals, Germany), and 
hemoglobin (cyanmethemoglobin method) were assayed 
within 3 hr of blood draws using a Hitachi U2001 spec-
trophotometer (Hitachi Instruments Ltd., USA), using 
standard reagent kits. Blood and plasma volume changes 
were calculated from hematocrit and hemoglobin using 
standard equations (Dill & Costill, 1974).
An additional 4 ml of venous blood was collected 
into lithium heparin tubes at rest and at 40 and 80 min of 
exercise and centrifuged at 5,000 rpm at 4 °C for 10 min, 
with plasma extracted into duplicate tubes and frozen 
at –60 °C until analysis. These samples were used for 
analysis of plasma carnitine fractions by radiometric 
methods using liquid scintillation as outlined by McGarry 
and Foster (1985).
Urinary carnitine excretion was determined in each 
treatment period by means of 24-hr urine collections 
before the D0 and D14 exercise trials. A 5-ml sample 
of mixed urine was collected and frozen at –80 °C until 
analysis, and the total volume of urine excreted over the 
24-hr period measured to the nearest milliliter. Urinary 
carnitine fractions were subsequently analyzed (McGarry 
& Foster, 1985).
Statistics
Because of the nature of the study design, comparisons 
between trials were restricted to D0 versus D14, with 
treatment (LC vs. P) as the between-subjects effect (i.e., 
to assess effect of exercise intensity on the whole-body 
metabolic response to P and LC supplementation) and 
D14 versus D15 (i.e., to assess effect of an acute altera-
tion in substrate availability on whole-body metabolic 
response to P and LC supplementation). All data were 
checked for normality of distribution and homogeneity of 
variance before analysis. Data were analyzed by two-way 
repeated-measures analysis of variance with time as a 
within-subject effect and treatment as a between-subjects 
effect. Change in values was analyzed by paired-samples 
t test, or differences between groups with independent-
samples t test (SPSS version 15.0, SPSS Inc., Chicago, 
IL). Significance was accepted at p < .05, and where 
significance was found, Tukey’s post hoc test was under-
taken to ascertain where it lay. All data are expressed as 
M ± SD unless otherwise specified.
Results
The results that follow are for 15 subjects (7 P, 8 LC). 
Unless otherwise specified in the results, differences 
were not observed between trials that were specific to a 
particular workload or between the two treatment groups.
The energy content and macronutrient composition 
of the 2-day preexercise diet for the D0 and D14 trials 
were 13.3 ± 1.4 MJ/day, 15% ± 1% protein, 60% ± 2% 
CHO, and 25% ± 1% fat and for the D15 trial were 13.4 
± 0.9 MJ/day, 15% ± 3% protein, 15% ± 4% CHO, and 
70% ± 4% fat. For all trials, mean protein intake was 1.6 
g · kg BM–1 · day–1, whereas CHO and fat intakes were 
6.7 ± 1.4 g · kg BM–1 · day–1 and 86 ± 11 g/day for the 
D0 and D14 trials compared with 1.7 ± 0.2 g/kg BM and 
246 ± 18 g for the D15 trial.
Preexercise diet and exercise controls ensured no 
differences in preexercise body mass between the D0 and 
D14 trials (P: 72.6 ± 9.8 and 73.1 ± 9.4 kg; LC: 76.6 ± 
7.9 and 76.7 ± 8.1 kg) and preexercise plasma glucose 
concentrations (D0, D14, and D15 P: 5.7 ± 0.5, 5.6 ± 
0.5, 5.8 ± 0.5 mmol/L; LC: 5.8 ± 0.3, 5.4 ± 0.6, 5.6 ± 
0.6 mmol/L). There was a small yet significant loss of 
BM between the D14 and D15 trials in both groups (P 
0.8 ± 0.8 kg, LC 0.5 ± 0.5 kg; p < .05) but no difference 
(p = .77) in preexercise hematocrit between these two 
trials. There were no differences in median (range) fluid 
intake (990 [600–1,880] ml, p = .70) or BM change 
during the exercise trial (–100 [–850 to 450] g, p = .71) 
between trials in either group or between groups. Blood 
and plasma volume fell with each increase in workload, 
but there were no differences between trials within or 
between the two groups, so no correction of blood vari-
ables was undertaken. The lack of difference between 
trials for blood volume, plasma volume, NBM change, 
and fluid intake indicates there was a similar change in 
hydration status throughout exercise in all trials, with no 
difference between the two treatment groups.
Mean exercise HR (Figure 1) and rating of perceived 
exertion (8 ± 1 and 17 ± 1 for 20% and 80% workloads in 
both P and LC groups) increased with each power output 
in all trials (p < .05). HR was higher (Figure 1) in the P 
than LC at the 20% workload at D14 and was higher in P 
than LC at the 20%, 40%, and 60% workloads on D15 (p 
< .05), with no difference between groups at any workload 
during the D0 trial. Rating of perceived exertion did not 
differ between trials in either group.
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Figure 1 — Heart-rate response during graded exercise on (A) Day 0, (B) Day 14, and (C) Day 15, M ± SD. *Significant difference 
between L-carnitine (LC) and placebo (P) trials, p < .05.
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Carnitine Fractions
All carnitine fractions were within the reported normal 
ranges, and there was no difference between groups at 
D0 (Table 3). Supplementation increased resting plasma 
total (TC) and free (FC) carnitine fractions in the LC 
group (p < .01 at both D14 and D15 compared with 
D0), with no change in the P group. Urinary carnitine 
excretion was elevated after D14 supplementation for 
all carnitine fractions (LC group: D0 TC 263 ± 58, FC 
98 ± 52, acyl-carnitine [AC] 166 ± 49; D14 TC 1,345 ± 
328, FC 860 ± 286, AC 485 ± 247 μmol/day, p < .01), 
with no change in the P group (D0 TC 293 ± 93, FC 140 
± 108, AC 153 ± 57; D14 TC 309 ± 112, FC 125 ± 82, 
AC 183 ± 38 μmol/da.
Compared with resting values, plasma TC increased 
(p < .05 for LC group, n.s. for P group) and FC fell (p < 
.05, except for LC D0 trial) at the 80% workload for both 
D0 and D14 trials in both groups. Plasma AC increased at 
the 80% workload compared with both rest and the 40% 
workload in all trials (p < .05) except for the D0 trial in P. 
As a result, the AC:FC ratio was higher at the 80% workload 
than at rest or the 40% workload in all trials for both groups 
(Figure 2; p < .05). The high fat intake increased plasma 
TC and AC during exercise compared with D14, but this 
reached significance only in the LC group (p < .05). The 
high fat intake also prevented a fall in free carnitine at 
80% VO2peak and appears to have induced a greater change 
in TC and AC responses to exercise, particularly in the LC 
group, where plasma TC and AC increased progressively 
as workload increased (p < .05, Table 3).
Metabolic Responses
The high fat intake resulted in higher plasma FFA con-
centrations at rest and during exercise (p < .01; Table 4), 
a higher blood glycerol concentration during exercise 
at all workloads (p < .01; Table 4), and a lower blood 
lactate at the 80% workload compared with the D0 or 
D14 trial in both groups, with no differences in these 
variables observed between D0 and D14. There was 
no difference between D0 and D14, between D14 and 
D15, or between groups for bicarbonate, pH, and pCO2. 
There was a significant effect of time for plasma glucose, 
lactate, bicarbonate, pH, and pCO2 (p < .05), with the 
80% workload being different from rest. Although blood 
lactate concentration (Table 4) was somewhat lower at 
the 80% workload after 2 weeks of LC supplementation 
than at D0, this did not reach statistical significance (mean 
difference 0.8 mM, 95% CI 0.3 to –1.8, p = .12). Plasma 
glucose was not different between LC and P groups on 
the D0 or D14 trials but was lower during exercise in 
the LC group on the D15 trial (p < .05 for 40% and 60% 
intensities; Figure 3).
Substrate Utilization
VO2, carbon dioxide exhalation (VCO2), and minute 
ventilation (VE) all increased with each power output 
increment (p < .01) and did not differ between treatment 
groups or between D0 and D14 trials. VO2 was higher 
on the D15 trial than at D0 and D14 at each workload (p 
< .01), whereas VCO2 did not differ between trials. VE 
was higher on the D15 trial than at D0 and D14 at the 
80% workload in both treatment groups, with no differ-
ence between trials at the other workloads. Respiratory-
exchange ratio (RER) was not different between D0 and 
D14 in either group but was lower during the D15 trial 
than on both D0 and D14 in both P and LC (p < .01). 
At D0 and D14, RER was stable from the 20% to 60% 
workloads, then rose during the 80% workload (p < .01), 
but during the D15 trial the increase in RER began at the 
60% workload (p < .05).
There was no difference in the estimated rate of 
whole-body CHO or fat oxidation between treatment 
groups at either D0 or D14 (Figures 4 and 5). The 24-hr 
Table 3 Plasma Carnitine Fractions (μmol/L) at Rest and After Exercise at 40% and 80%
of Workload at VO2peak, M ± SD
Placebo L-Carnitine
Fraction Trial Rest 40% workload 80% workload Rest 40% workload 80% workload
Total Day 0 49 ± 9 47 ± 7 55 ± 10 44 ± 10 45 ± 9 53 ± 8b
Day 14 46 ± 6 47 ± 7 55 ± 8 62 ± 9a 66 ± 13a 74 ± 14a,b
Day 15 53 ± 7 56 ± 4 65 ± 6b 64 ± 14a 78 ± 17a,b 95 ± 22a,b,c
Free Day 0 38 ± 8 37 ± 6 34 ± 5b,c 35 ± 6 35 ± 4 31 ± 2
Day 14 37 ± 4 37 ± 3 33 ± 4b,c 48 ± 4a 49 ± 4a 44 ± 5a,b,c
Day 15 38 ± 5 39 ± 3 38 ± 3d 45 ± 7a 47 ± 6a 47 ± 5a
Acyl Day 0 11 ± 2 10 ± 4 22 ± 6 9 ± 8 10 ± 8 22 ± 8b
Day 14 9 ± 4 10 ± 5 23 ± 4b 14 ± 9 18 ± 12 30 ± 12b
Day 15 14 ± 4 16 ± 5 27 ± 4b 20 ± 15 31 ± 16b,d 48 ± 18b,d
aSignificantly greater than L-carnitine, Day 0, and placebo for the same trial, p < .05. bSignificantly different from resting value, p < .05. cSignificantly 
different from 40% workload, p < .05. dSignificantly different from the same workload in the other trials for the same group, p < .05.
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Figure 2 — Plasma acyl-carnitine-to-free-carnitine ratio on (A) Day 0, (B) Day 14, and (C) Day 15, M ± SD. P = placebo; LC = 
L-carnitine. *Significantly greater than P group, p < .05. aSignificantly greater than rest for all trials, p < .05. bSignificantly greater 
than 40% workload for all trials, p < .05.
high fat intake changed the contribution of CHO and fat 
to metabolism in both the P and LC groups compared 
with D14, particularly in the first three workloads (p 
< .05; Figures 4 and 5). The rate of fat oxidation was 
lowest at the 20% workloads, with peak rates of oxida-
tion at the 60% workload (p < .01 compared with 20%), 
with no further change from the 60% to 80% workload 
in all trials. In the D15 trials there was also a significant 
difference between the 20% and 40% workloads (p < 
.05) that was not present at either the D0 or D14 trial. 
Total estimated whole-body fat oxidation over 60 min of 
exercise was not different between LC and P on the D0 
trial and was not different between LC and P on the D14 
trial (P 21 ± 7 g, LC 29 ± 10 g). Total fat oxidation over 
60 min of exercise increased (p < .01) from D14 to D15 
trials in both LC and P groups.
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Discussion
In the current study there was a lower HR in the LC group 
during exercise at 20% of VO2peak in the D14 trial and at 
20%, 40%, and 60% of VO2peak in the D15 trial than with 
P but no difference between groups during the D0 trial, a 
greater alteration in plasma AC:FC ratio under conditions 
of high fat availability in the LC group than with placebo, 
a lower plasma glucose in the LC group during exercise 
on the D15 trial than with P but not during the D0 and D14 
trials under conditions of high CHO availability, and no 
significant difference in the whole-body estimated rates 
of CHO and fat oxidation at any exercise intensity after 
LC supplementation compared with P.
The observed difference in HR response to the low 
intensities of exercise (20%, 40%, and 60% of peak 
power) between the LC and P groups in the D15 trial 
may reflect an effect of carnitine on cardiac-muscle 
contractility. Gurlek et al. (2000) observed a greater 
increase in left-ventricular ejection fraction after 4 weeks 
of LC supplementation in patients with ischemic cardio-
myopathy. Bartels et al. (1992) observed an increase in 
cardiac output after intravenous administration of LC in 
normotensive coronary artery disease patients. Greig, 
Jones, Cooper, Sargeant, and Forte (1987) observed 
a lower HR during exercise at 50% of VO2peak after 2 
weeks of oral LC supplementation in normal active 
humans, and Natali et al. (1993) reported a lower HR 
after LC infusion. The current study is consistent with 
these previous observations and lends support to a pos-
sible positive inotropic effect and negative chronotropic 
effect of elevated plasma carnitine on cardiac muscle 
in the presence of high fat availability. The mechanism 
underlying this effect requires more detailed cardiovas-
cular function investigation.
van Loon et al. (2001) demonstrated a decline in 
muscle FC on going from rest to exercise at intensities 
of >40% of maximal workload (Wmax) and suggested 
that this reduction in FC availability may be a primary 
driving factor in reducing fat oxidation during exercise 
at higher intensities (75% Wmax). Thus, for LC supple-
mentation to have an effect on skeletal-muscle sub-
strate utilization during exercise it would seem that an 
increase in the FC pool of that tissue must be established, 
and the intensity would need to be sufficiently high to 
alter FC availability. Therefore, the lack of any difference 
between trials in the metabolic response to exercise at 
baseline (D0) and after 2 weeks of supplementation 
in the current study strongly suggests that there were 
no differences in the FC availability or AC:FC ratio in 
any tissues that were contributing to the whole-body 
metabolic response to exercise. This suggestion is 
supported by the similar changes in plasma carnitine 
fractions and AC:FC ratio in the current study at 
Table 4 Plasma Free Fatty Acids, Blood Glycerol, and Blood Lactate (mmol/L) for Placebo 
and L-Carnitine Groups, M ± SD
                                              Workload
Variable Group Trial Rest 20% 40% 60% 80%
Free fatty acids Placebo Day 0 0.23 ± 0.20 0.21 ± 0.17 0.28 ± 0.19 0.28 ± 0.14 0.21 ± 0.05
Day 14 0.20 ± 0.21 0.21 ± 0.17 0.28 ± 0.18 0.27 ± 0.15 0.19 ± 0.04
Day 15 0.48 ± 0.12a 0.39 ± 0.10a 0.52 ± 0.17a 0.49 ± 0.13a 0.43 ± 0.28a
L-carnitine Day 0 0.36 ± 0.23 0.33 ± 0.25 0.42 ± 0.36 0.41 ± 0.33 0.29 ± 0.20
Day 14 0.35 ± 0.20 0.37 ± 0.19 0.55 ± 0.26 0.51 ± 0.22 0.36 ± 0.16
Day 15 0.57 ± 0.30a 0.49 ± 0.22a 0.68 ± 0.32a 0.74 ± 0.37a 0.65 ± 0.33a
Glycerol Placebo Day 0 0.06 ± 0.04 0.07 ± 0.04 0.13 ± 0.06 0.14 ± 0.06 0.20 ± 0.07
Day 14 0.05 ± 0.03 0.06 ± 0.02 0.10 ± 0.03 0.12 ± 0.04 0.18 ± 0.05
Day 15 0.06 ± 0.03 0.15 ± 0.06b,c 0.20 ± 0.06b 0.31 ± 0.08b 0.37 ±0.06b
L-carnitine Day 0 0.08 ± 0.04 0.09 ± 0.05 0.14 ± 0.07 0.17 ± 0.09 0.23 ± 0.11
Day 14 0.07 ± 0.03 0.10 ± 0.04 0.16 ± 0.06 0.22 ± 0.08 0.27 ± 0.08
Day 15 0.10 ± 0.08 0.15 ± 0.09b,c 0.25 ± 0.08b 0.33 ± 0.11b 0.45 ± 0.12b
Lactate Placebo Day 0 0.87 ± 0.37 0.82 ± 0.41 0.95 ± 0.33 1.51 ± 0.47 5.99 ± 0.94
Day 14 0.90 ± 0.32 0.78 ± 0.26 0.93 ± 0.35 1.45 ± 0.51 5.84 ± 1.40
Day 15 0.68 ± 0.45 0.67 ± 0.34 0.77 ± 0.37 1.31 ± 0.47 5.33 ± 0.91d
L-carnitine Day 0 0.74 ± 0.14 0.67 ± 0.20 0.87 ± 0.34 1.36 ± 0.32 6.05 ± 1.40
Day 14 0.64 ± 0.14 0.66 ± 0.20 0.77 ± 0.27 1.31 ± 0.46 5.29 ± 1.89
Day 15 0.62 ± 0.16 0.53 ± 0.14 0.69 ± 0.28 0.99 ± 0.23 4.99 ± 1.66d
aSignificantly greater than Day 0. bSignificantly greater than Day 0 and Day 14. cLower than 60% and 80% workloads for all trials, p < .05. dSig-
nificantly lower than Day 0.
Carnitine, Workload, and Preexercise Diet  393
Figure 3 — Plasma glucose response during graded exercise on (A) Day 0, (B) Day 14, and (C) Day 15, M ± SD. P = placebo; LC 
= L-carnitine. *Significant difference between LC and P, p < .05.
baseline and after 2 weeks LC supplementation across 
the exercise intensities studied. It should be noted 
that the change in plasma AC:FC ratio is thought to 
reflect changes in skeletal-muscle AC:FC ratio during 
exercise (Friolet, Hoppeler, & Krahenbuhl, 1994). The 
higher AC:FC ratio in the LC group than with P during 
the highest intensity of exercise on the D15 trial could 
reflect greater acetyl-group buffering by FC in metaboli-
cally active tissues (Friolet et al., 1994), which is likely 
a result of increased acetyl-CoA formation through 
pyruvate dehydrogenase, thus indicating a higher rate 
of glycolysis in the LC group (Stephens, Constantin-
Teodosiu, & Greenhaff, 2007). This is consistent with 
the observations of Wall et al. (2010), who found 
increased pyruvate dehydrogenase activity in higher 
intensity exercise after oral carnitine supplementa-
tion. However, the changes noted in the current study 
did not result in any whole-body substrate-utilization 
differences assessed using indirect calorimetry at this 
intensity. The lack of effect on measured substrate 
utilization may also be influenced by the relatively 
short exercise duration at each workload (20 min); 
indeed, this may explain why we have not been able to 
replicate our previous observation of higher total CHO 
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Figure 4 — Estimated rate of whole-body carbohydrate (CHO) oxidation during exercise on (A) Day 0, (B) Day 14, and (C) Day 
15, M ± SD. P = placebo; LC = L-carnitine. *Rate of CHO oxidation significantly lower in D15 than D14 in both P and LC, p < .01. 
aRate of CHO oxidation significantly lower in D15 than D14 in P only, p < .01. The rates of CHO and fat oxidation were calculated 
at 80 min and are shown as dashed lines to present a more complete comparison between trials, despite the fact that ventilatory 
parameters at 80% VO2peak did not achieve steady state, being affected by changes in the bicarbonate pool (blood lactate >4 mmol/L, 
pCO2 and bicarbonate levels decreasing).
oxidation over 60 min of exercise after 2 weeks of LC 
supplementation than with P (Abramowicz & Galloway, 
2005). A carnitine-induced increase in glucose oxidation 
by cardiac muscle, as reported using an in vitro model by 
Rodgers et al. (2001), would likely not be large enough to 
be detectable using whole-body indirect calorimetry mea-
surements. The increased glucose oxidation of 0.5 μmol · 
g–1 · min–1 in the presence of carnitine noted by Rodgers 
et al. (2001) would amount to only a 0.03-g/min change 
in glucose oxidation for an average human heart mass of 
300 g. However, any change in cardiac-muscle substrate 
oxidation could be an important avenue to explore in an 
attempt to explain the observed differences in HR noted 
between trials in the current study.
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Figure 5 — Estimated whole-body rate of fat oxidation during exercise on (A) Day 0, (B) Day 14, and (C) Day 15, M ± SD. P = 
placebo; LC = L-carnitine. *Significantly higher on D15 than D0 and D14 in both P and LC, p < .01.
The difference in plasma glucose concentration 
observed during the D15 trial combined with elevated 
plasma TC, FC, and AC could also be explained by an 
increased nonoxidative glucose disposal effect of LC 
rather than any change in glucose oxidation. Previous 
studies have shown that an elevation of plasma carnitine 
concentration increases nonoxidative glucose disposal 
during hyperinsulinemic euglycemic clamps in controls 
and in patients with Type 2 diabetes (Giancaterini et 
al., 2000; Mingrone et al., 1999) and increases glucose 
disposal during intravenous glucose-tolerance testing 
(De Gaetano, Mingrone, Castagneto, & Calvani, 1999), 
and we have recently shown this to occur after oral LC 
supplementation in lean active males (Galloway, Craig, 
& Cleland, 2011). Furthermore, Stephens et al. (2006) 
have observed increased glycogen storage in skeletal 
muscle after carnitine infusions. This potential effect of 
carnitine on glucose disposal could be important in longer 
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duration exercise or in recovery of glycogen stores after 
prolonged exercise.
Conclusion
The results of this study indicate that 2 weeks supplemen-
tation of 3 g LC per day with high CHO availability does 
not result in a significant change in whole-body substrate 
metabolism during 20-min bouts of exercise over a range 
of intensities (20–80% of VO2peak). However, under condi-
tions of high fat availability, there is evidence of an effect 
of LC supplementation, with a decline in blood glucose 
in the LC group compared with P and a reduction in the 
HR response to exercise. These alterations may reflect 
carnitine-induced changes in glucose disposal and oxida-
tion in a range of metabolically active tissues, but any 
changes in oxidation may be too small to be detected at 
the whole-body level. Future work may wish to focus 
on the potential beneficial effects of carnitine on cardio-
vascular responses to exercise, as well as on substrate 
availability over more prolonged exercise periods or on 
glycogen restoration in recovery from exercise, to further 
understand the specific roles of this dietary component.
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